³Ø²ñȯɽ
¸¦µæ¶ÈÀÓ













¥µ¥¤¥È¥Þ¥Ã¥×

¢£¿À¸ÍÄ«Æüɱ¡
--¿À¸Í»ÔÂèÆó¼¡µßµÞɱ¡--
¢©653-0801
¿À¸Í»ÔĹÅĶè˼²¦»ûÄ®3-5-25
Ï¢ÍíÀè
ÅÅÏá§ 078-612-5151¡ÊÂå¡Ë
£Æ£Á£Ø¡§078-612-5152
email¡§info@kobe-asahi-hp.com


¡¡
HOME¤ØÌá¤ë

¡¡

¢§³Ø²ñ³èư £±£¹£¹£¹Ç¯-£²£°£°£µÇ¯
¡Ê¥ê¥ó¥¯¤·¤Æ¤¤¤ë¤â¤Î¤ÏÆâÍÆ¤¬¤´Í÷¤¤¤¿¤À¤±¤Þ¤¹¡Ë
³«ºÅǯ·î ³Ø²ñ̾ ±é¼Ô ±éÂê̾
1999ǯ2·î Âè70²óÆüËܾò½´ïɳزñ¡¡¶áµ¦»ÙÉôÎã²ñ ¶â¼éÎÉ ´Î±ê¥¦¥¤¥ë¥¹¥Þ¡¼¥«¡¼±¢À­¤ÎËýÀ­»ý³À­´Î±ê¡ÊCPH¡Ë¤òÇØ·Ê¤È¤·¤Æ3ǯ¤Î·Ð²á¤ÇÁ£¼ðÍͲá·ÁÀ®¡ÊAH¡Ë¤«¤é´Î´â¡ÊHCC¡Ë¤Ø¤Î°Ü¹Ô¤¬¸«¤é¤ì¤¿°ì¾ÉÎã
1999ǯ6·î Âè35²óÆüËܴδ⸦µæ²ñ ¶â¼éÎÉ PEIT¼£ÎŸ塢´Î³°¤ËÇżïÀ­È¯°é¤·¤¿HCC¤Î°ì¾ÉÎã
1999ǯ10·î Âè41²óÆüËܾò½´ïɳزñ ¶â¼éÎÉ Èó£ÂÈó£Ã´Î´â¤Ë¤ª¤±¤ëTTV¤ÎÍÛÀ­Î¨¤ÈÍ¢·ìÎò¤Î¸¡Æ¤―£Â¡¦£Ã´Î´â¤È¤ÎÈæ³Ó―
1999ǯ10·î Âè63²óÆüËܾò½´ïÆâ»ë¶À³Ø²ñ¡¡¶áµ¦ÃÏÊý²ñ °ÂÆ£·ò¼£ ±éÂê̾Èó¸ø³«
1999ǯ12·î Âè33²óÆüËܴΡ³Ø²ñÀ¾Éô²ñ ¶â¼éÎÉ ±éÂê̾Èó¸ø³«
1999ǯ12·î Âè33²óÆüËܴΡ³Ø²ñÀ¾Éô²ñ ¶â¼éÎÉ ´ÎºÙ˦´â¡ÊHCC¡Ë¤ËÂФ¹¤ë¥¨¥¿¥Î¡¼¥ëÃíÆþÎÅË¡¡ÊPEIT¡Ë¤Î¹çÊ»¾É―´Î³°ÇżïÀ­Å¾°ÜÎã¤È´Î³°A-V¥·¥ã¥ó¥ÈÎã¤Ë¤Ä¤¤¤Æ
1999ǯ12·î Âè33²óÆüËܴΡ³Ø²ñÀ¾Éô²ñ °æËÜÊÙ honeymoon hepatitis¤È¤·¤ÆÈ¯¾É¤·¤¿HHV-6ñ³Ë¾É¤Î1Î㡾ÆÃ¤ËISHË¡¤Ë¤è¤ë¥¦¥¤¥ë¥¹´¶À÷ºÙ˦¤ÎƱÄê
2000ǯ2·î Âè72²óÆüËܾò½´ïɳزñ¡¡¶áµ¦»ÙÉôÎã²ñ °ÂÆ£·ò¼£ Lp-TAE¸å´ÎÇ¿áç¤òȯ¾É¤·¤¿´ÎºÙ˦´â¤Î°ìÎã
2000ǯ4·î Âè86²óÆüËܾò½´ïɳزñÂç²ñ ¶â¼éÎÉ £Ã·¿´Î±ê¤ËÂФ¹¤ëIFNÎÅË¡¸åÃø¸ú¤Ë¤â¤«¤«¤ï¤é¤º3ǯ¸å¡¢7ǯ¸å¤Ëȯ´â¤·¤¿´ÎºÙ˦´â¤Î°ì¾ÉÎã
2000ǯ6·î Âè36²óÆüËܴΡ³Ø²ñÁí²ñ ¶â¼éÎÉ £Ã·¿´Î±ê¤ËÂФ¹¤ëIFNÅêÍ¿ÎãµÚ¤Ó£Ã·¿´Î¹ÅÊѤ˹çÊ»¤·¤¿¸¶È¯À­¹Å²½À­ÃÀ´É±ê¤Î3¾ÉÎã
2000ǯ6·î Âè36²óÆüËܴδ⸦µæ²ñ ¶â¼éÎÉ ÌäÂê¾ÉÎ㸡Ƥ²ñ·Ð²á´Ñ»¡Ãæ¤ËCTAP½ê¸«¤Î±¢À­²½¤Ëȼ¤¤ÉÔÌÀÎÆ²½¤·¤¿Ä㥨¥³¡¼·ëÀá¤Î°ì¾ÉÎã
2000ǯ9·î Âè73²óÆüËܾò½´ïɳزñ¡¡¶áµ¦»ÙÉôÎã²ñ °ÂÆ£·ò¼£ ¹âÅ٤β«áÕ¤òÄ褷¹­ÈÆÀ­´Î²õ»à¤òȼ¤Ã¤¿µÞÀ­´Î±êÁü¤Çȯ¾É¤·¤¿¹âÎð¼Ô¼«¸ÊÌȱÖÀ­´Î±ê¡¦·¿¤Î°ìÎã
2000ǯ9·î Âè37²óÆüËÜÊ¢ÉôµßµÞ°å³Ø²ñÁí²ñ ¶ñ¸÷À® µÞÀ­Ê¢¾É¤ÈÊ¢ÉôÂçÆ°Ì®áîÀÚÇ÷ÇËÎö¤Î´ÕÊ̤˶ìθ¤·¤¿¾ÉÎã
2000ǯ10·î Âè3²ó¹ñºÝ´Î¹ÅÊѴδ⥷¥ó¥Ý¥¸¥¦¥à ¶â¼éÎÉ TTV-positivity and transfusion history in non-B and non-C HCC compared with HBV- and HCV-positive cases
2000ǯ11·î Âè33²óÆüËܴΡ³Ø²ñÅìÉô²ñ ¶â¼éÎÉ ±éÂê̾Èó¸ø³«
2001ǯ2·î Âè74²óÆüËܾò½´ïɳزñ¡¡¶áµ¦»ÙÉôÎã²ñ »°ÅÄ·ÉÆó ·ìÀ­¤Îç¹À­Ê¢¿å¤òÄ褷¤¿ç¹²¾À­Ç¹Ë¦¤Î°ìÎã
2001ǯ4·î Âè87²óÆüËܾò½´ïɳزñÁí²ñ ¶â¼éÎÉ Áá´ü´ÎºÙ˦´â¤Ë¤ª¤±¤ëĹ´üͽ¸å¤Î¸¡Æ¤
2001ǯ4·î Âè101²óÆüËܳ°²Ê³Ø²ñÁí²ñ ¶ñ¸÷À® ´§Æ°Ì®¥Ð¥¤¥Ñ¥¹½Ñ¤Ë¤ª¤±¤ëµõ·ìºÆÞõή¾ã³²¡Ý·ìÃæ»ÀÁÇÇ»ÅÙ¤ÈCaÙɹ³ºÞ¤Î¸úǽ
2001ǯ5·î Âè37²óÆüËܴΡ³Ø²ñÁí²ñ ¶â¼éÎÉ ±éÂê̾Èó¸ø³«
2001ǯ5·î Âè29²óÆüËÜ·ì´É³°²Ê³Ø²ñ³Ø½ÑÁí²ñ ¶ñ¸÷À® ´§Æ°Ì®¥Ð¥¤¥Ñ¥¹½Ñ¤Ë¤ª¤±¤ëµõ·ìºÆÞõή¾ã³²―ºÆÞõή»þ·ìÃæ»ÀÁÇÇ»Å٤ȥ«¥ë¥·¥¦¥àÙɹ³ºÞ¤Î¸úǽ
2001ǯ6·î Âè37²óÆüËܴδ⸦µæ²ñ ¶â¼éÎÉ ¥é¥¸¥ªÇȾƼÞÎÅË¡¡ÊRFA¡Ë¤Ë¤è¤ë¹çÊ»¾É¡¦ÃÀ´É»½ý¤Î°ì¾ÉÎã
2001ǯ6·î Âè37²óÆüËܴδ⸦µæ²ñ ¶â¼éÎÉ ´Î±ê¥¦¥¤¥ë¥¹¥Þ¡¼¥«¡¼±¢À­¤ÎËýÀ­»ý³À­´Î±ê¡ÊCPH¡Ë¤òÇØ·Ê¤È¤·¤Æ3ǯ¤Î·Ð²á¤ÇÁ£¼ðÍͲá·ÁÀ®(AH)¤«¤é´ÎºÙ˦´â¡ÊHCC¡Ë¤Ø¤Î°Ü¹Ô¤¬¸«¤é¤ì¤¿°ì¾ÉÎã
2001ǯ9·î Âè75²óÆüËܾò½´ïɳزñ¡¡¶áµ¦»ÙÉôÎã²ñ Á°ÀîÍÛ»Ò ´ÎºÙ˦´â¤ËÂФ¹¤ë¥é¥¸¥ªÇȾƼÞÎÅË¡¡ÊRFA¡Ë¤Î¸¡Æ¤
2001ǯ10·î DDW-JAPAN¡¡2001Âè5²óÆüËܴΡ³Ø²ñÂç²ñ ¶â¼éÎÉ ±éÂê̾Èó¸ø³«
2001ǯ10·î DDW-JAPAN¡¡2001Âè5²óÆüËܴΡ³Ø²ñÂç²ñ ¶â¼éÎÉ ¿Ê¹Ô´Î´â¡ÊHCC¡Ë¤ËÂФ¹¤ëÀ¸Âδΰܿ¢¤Ë¤ª¤±¤ëÆâ²Ê°å¤ÎÁªÂò
2001ǯ12·î Âè34²óÆüËܴΡ³Ø²ñÀ¾Éô²ñ ¶â¼éÎÉ ¥¢¥ë¥³¡¼¥ë´Î¹ÅÊѤˤߤé¤ì¤¿²á·ÁÀ®·ëÀá¤Î°ìÎã
2001ǯ12·î Âè34²óÆüËܴΡ³Ø²ñÀ¾Éô²ñ °æËÜÊÙ µÞÀ­È¯¾É¤·½Å¾ÉµÞÀ­´Î±ê¤ÎÁÈ¿¥Áü¤òÄ褷¤¿¹âÎð¼Ô¼«¸ÊÌȱÖÀ­´Î±ê­µ·¿¤Î2Îã
2002ǯ2·î Âè76²óÆüËܾò½´ïɳزñ¡¡¶áµ¦»ÙÉôÎã²ñ Á°ÀîÍÛ»Ò ÂçIJ´â¤Îȯ°é¿ÊŸ¤ÈޱŽÎŽßŽÄް޼޽µÚ¤ÓºÙ˦Áý¿£¤Î´ØÍ¿¤Ë¤Ä¤¤¤Æ
2002ǯ4·î Âè88²óÆüËܾò½´ïɳزñ ¶â¼éÎÉ C·¿ËýÀ­´Î±ê¤Ë¤ª¤±¤ë´Î»éËò½¤Î̵ͭ¤Ë¤è¤ëȯ´âΨµÚ¤Óȯ´â»þ¤ÎÉÂÍý³ØÅª¸¡Æ¤
2002ǯ5·î Âè38²óÆüËܴδ⸦µæ²ñ ¶â¼éÎÉ CTAP½ê¸«ÍÛÀ­²½(S7¡Ë4ǯ¸å¡¢AFP L3ʬ²èÍÛÀ­²½3ǯ¸å¤ËS7¤Î¾Éô°Ì¤Ëȯ´â¤·¤¿Áá´üHCC¤Î°ì¾ÉÎã
2002ǯ6·î Âè38²óÆüËܴΡ³Ø²ñÁí²ñ Á°ÀîÍÛ»Ò Áá´ü´ÎºÙ˦´â¡ÊHCC¡Ë¤Î¼£ÎÅÀ®ÀӤθ¡Æ¤¡ÝPEIT¼£ÎŤòÃæ¿´¤Ë¡Ý
2002ǯ9·î Âè77²óÆüËܾò½´ïɳزñ¶áµ¦»ÙÉôÎã²ñ °ÂÆ£·ò¼£ AMA¡¢¹³PDH¹³ÂΤϱ¢À­¤Ç¤¢¤Ã¤¿¤¬IgA·¿OGDC¡¾E2¹³ÂΤ¬Ã±ÆÈ¤Ç¸¡½Ð¤µ¤ì¡¢¤«¤Ä¥·¥§¡¼¥°¥ì¥ó¾É¸õ·²¡¢CRST¾É¸õ·²¡¢ËýÀ­´ØÀá¥ê¥¦¥Þ¥Á¤ò¹çÊ»¤·¤¿¡¢¸¶È¯À­ÃÀ½ÁÀ­´Î¹ÅÊÑ¡¾¼«¸ÊÌȱֽÅÊ£¾É¸õ·²¤Î°ìÎã
2002ǯ10·î DDW¡¾JAPAN2002¡¡Âè44²óÆüËܾò½´ïɳزñÂç²ñ ¶â¼éÎÉ ÂçIJ´â´Îž°Ü¤Ë´Ø¤¹¤ë¥¢¥Ý¥È¡¼¥·¥¹¤ÈºÙ˦Áý¿£Ç½¤Î¸¡Æ¤
2002ǯ10·î DDW¡¾JAPAN2002¡¡Âè6²óÆüËܴΡ³Ø²ñÂç²ñ Á°ÀîÍÛ»Ò Liver enrichž¼Ì³ËÃÁÇòÀ÷¿§¡ÊHNF-4¦Á¡¢HNF-3¦Â¡Ë¤Ë¤è¤êstem cellͳÍè¤È¹Í¤¨¤é¤ì¤¿HCC¡¢CCC¡¡mixed tumor
2002ǯ10·î DDW-JAPAN2002¡¡Âè6²óÆüËܴΡ³Ø²ñÂç²ñ °æËÜÊÙ HCV´¶À÷¼Ô¤Ë¤ª¤±¤ë¥¦¥¤¥ë¥¹ÇÓ½üµÚ¤Ó»ý³¤Î¥á¥«¥Ë¥º¥à¤Ë´Ø¤¹¤ë¸¦µæ
2002ǯ10·î DDW-JAPAN2002¡¡Âè6²óÆüËܴΡ³Ø²ñÂç²ñ ¶â¼éÎÉ ¥¢¥ë¥³¡¼¥ë¿·ìÀ­·ëÀáÉÂÊѤθ¡Æ¤
2002ǯ11·î Âè34²óÆüËܴΡ³Ø²ñÅìÉô²ñ ¶â¼éÎÉ CTAP¤ÇÇ»À÷¤µ¤ìCTA¤Çperfusion defect¤ò¼¨¤·ÇØç¹Æ°Ì®¡¢ç¹Æ¬Æ°Ì®¤Î·ì´É°Û¾ï¤¬¸¶°ø¤È¹Í¤¨¤é¤ì¤¿S6 3cmÂç¹â¥¨¥³¡¼SOL¤Î°ì¾ÉÎã
2002ǯ11·î

Âè34²óÆüËܴΡ³Ø²ñÅìÉô²ñ

Á°ÀîÍÛ»Ò ºÆÈ¯¤ò·«¤êÊÖ¤·²èÁü¾åHCC¤È¤Î´ÕÊ̤¬º¤Æñ¤Ç¤¢¤Ã¤¿±ê¾ÉÀ­µ¶¼ðáç¤Î°ìÎã
2003ǯ2·î Âè78²óÆüËܾò½´ïɳزñ¶áµ¦»ÙÉôÎã²ñ °ÂÆ£·ò¼£ ¹³LKM-1¹³ÂΤ¬¸¡½Ð¤µ¤ì¤¿­µ·¿¼«¸ÊÌȱÖÀ­´Î±ê¤Î£±Îã
2003ǯ3·î Âè70²óÆüËܾò½´ïÆâ»ë¶À³Ø²ñ¶áµ¦ÃÏÊý²ñ °ÂÆ£·ò¼£ ¼ê½ÑÎò¤Î¤Ê¤¤¥¤¥ì¥¦¥¹¾ÉÎã¤Î¸¡Æ¤
2003ǯ4·î Âè89²óÆüËܾò½´ïɳزñÁí²ñ ¶â¼éÎÉ ¶Ë¾®´ÎºÙ˦´â¡ÊHCC¡Ë¤ÎPEIT¼£ÎÅÀ®ÀӤθ¡Æ¤
2003ǯ5·î Âè39²óÆüËܴΡ³Ø²ñÁí²ñ ¶â¼éÎÉ CTAP½ê¸«ÍÛÀ­²½5,6ǯ¸å¡¢AFP¡¡L3ʬ²èÍÛÀ­²½3,4ǯ¸å¤Ë¤½¤ì¤¾¤ìS7¤Ë¹âʬ²½´â¡¢S3¤ËÃæÊ¬²½´â¤¬¡¢°Û»þÀ­È¯´â¤·¤¿HCC¤Î°ì¾ÉÎã
2003ǯ5·î Âè39²óÆüËܴΡ³Ø²ñÁí²ñ¡Ê¥é¥ó¥Á¥ç¥ó¥»¥ß¥Ê¡¼¡Ë ¶â¼éÎÉ Ãϰè°ìÈÌɱ¡¤Ë¤ª¤±¤ë´Î¡Î×¾²15ǯ¤Î·Ð¸³
2003ǯ5·î Âè39²óÆüËܴΡ³Ø²ñÁí²ñ ¶â¼éÎÉ Î×¾²É´ü­µ¡¢¶Ë¾®´ÎºÙ˦´â¡ÊHCC¡Ë¤ÎPEIT¼£ÎÅÀ®ÀӤθ¡Æ¤
2003ǯ5·î Âè39²óÆüËܴΡ³Ø²ñÁí²ñ °æËÜÊÙ ­µ·¿¼«¸ÊÌȱÖÀ­´Î±ê¤Ë¤ª¤±¤ë¹³LKM-1¹³ÂΤθ¡½Ð¡¢ÍÛÀ­Îã¤Î¸¡Æ¤
2003ǯ6·î Âè39²óÆüËܴδ⸦µæ²ñ ¶â¼éÎÉ C·¿ËýÀ­´Î±ê¤òÇØ·Ê¤Ëstem cellͳÍè¤È¹Í¤¨¤é¤ì¤¿HCC¡¦CCC¡¡mixed¡¡tumor
2003ǯ6·î Âè39²óÆüËܴδ⸦µæ²ñ ¶â¼éÎÉ B·¿µÚ¤ÓC·¿´Î¹ÅÊѤòÇØ·Ê¤ËȯÀ¸¤·¤¿HCC¡¦CCC¡¡mixed¡¡tumor¤Î2¾ÉÎã
2003ǯ9·î Âè79²óÆüËܾò½´ïɳزñ¶áµ¦»ÙÉôÎã²ñ ÉØÌÚ½¨°ì ŽØŽÊŽÞŽËŽÞŽØŽÝÊ»ÍÑÎÅË¡Ãæ¤ËÌÖËìÃæ¿´ÀÅÌ®Êĺɾɤò¹çÊ»¤·¤¿°ì¾ÉÎã
2003ǯ10·î Âè71²ó¾Ã²½´ïÆâ»ë¶À³Ø²ñ¶áµ¦ÃÏÊý²ñ »°ÅÄ·ÉÆó ¼£ÎÅÊý¿Ë¤Î·èÄê¤Ë¶ìθ¤·¤¿Â¿È¯À­ÂçIJ¥Ý¥ê¡¼¥×¤Î°ìÎã
2003ǯ10·î Âè7²óÆüËܴΡ³Ø²ñÂç²ñ ¶â¼éÎÉ IFN¤È¥ê¥Ð¥Ó¥ê¥óÊ»ÍÑÎÅË¡¤ÎÉûºîÍѤθ¡Æ¤
2003ǯ11·î Âè35²óÆüËܴΡ³Ø²ñÀ¾Éô²ñ ¶â¼éÎÉ È󥢥륳¡¼¥ëÀ­»éËÃÀ­´Î±ê¡ÊNASH¡Ë¤ÎÎ×¾²ÉÂÍý³ØÅª¸¡Æ¤¡Ý»éËôΤȤÎÈæ³Ó¡Ý
2003ǯ11·î Âè35²óÆüËܴΡ³Ø²ñÀ¾Éô²ñ ¶â¼éÎÉ CTAP¤Ë¤ÆÇ»À÷¡¢CTA¤Ë¤ÆË³·ìÀ­½ê¸«¤òÄ褷¤¿¹âʬ²½·¿HCC¤Î°ì¾ÉÎã
2003ǯ11·î Âè35²óÆüËܴΡ³Ø²ñÀ¾Éô²ñ °æËÜÊÙ ¹³LKM-1¹³ÂΤ¬¸¡½Ð¤µ¤ì¤¿£É·¿¼«¸ÊÌȱÖÀ­´Î±ê¤Î2Îã
2004ǯ2·î Âè80²óÆüËܾò½´ïɳزñ¶áµ¦»ÙÉôÎã²ñ °ÂÆ£·ò¼£ ç¹Æ¬Æ°Ì®-ÌçÌ®¥·¥ã¥ó¥È¤òÍ­¤·¤¿Æñ¼£À­Ê¢¿å¤ËÂФ·¥Ç¥ó¥Ð¡¼Ê¢¹Ð¡¦ÀÅÌ®¥·¥ã¥ó¥È½Ñ¤òÍѤ¤¤¿¾ÉÎã
2004ǯ6·î Âè40²óÆüËܴΡ³Ø²ñÁí²ñ ¶â¼éÎÉ C·¿ËýÀ­´Î±ê¤ËÂФ¹¤ëIFN¦Á-2b¡Ü¥ê¥Ð¥Ó¥ê¥óÎÅË¡¤Ë¤ª¤±¤ë¡¢IFN¦ÂÊ»ÍÑÎÅË¡¤ÎÎ×¾²Åª°ÕµÁ¤È¥¦¥¤¥ë¥¹¸º¾¯Î¨¤Î¸¡Æ¤
2004ǯ6·î Âè40²óÆüËܴΡ³Ø²ñÁí²ñ ¶â¼éÎÉ ÈóÄ귿ŪÂç·¿¹âʬ²½·¿´Î´â2ÀÚ½üÎã¤ÎÎ×¾²ÉÂÍý³ØÅª¸¡Æ¤
2004ǯ6·î Âè40²óÆüËܴΡ³Ø²ñÁí²ñ °æËÜÊÙ ¹³¥»¥ó¥È¥í¥á¥¢¹³ÂΤ¬Ã±ÆÈÍÛÀ­¤Ç¾¤ÎÀ÷¿§·¿¤Î¹³³Ë¹³ÂΤ¬±¢À­¤Î£É·¿¼«¸ÊÌȱÖÀ­´Î±ê
2004ǯ6·î Âè40²óÆüËܴδ⸦µæ²ñ ¶â¼éÎÉ ´Î¥«¥ë¥Á¥Î¥¤¥É¼ðáç¤Î2ÀÚ½üÎã-ÁÈ¿¥È¯À¸¤òÃæ¿´¤Ë-
2004ǯ6·î Âè40²óÆüËܴδ⸦µæ²ñ Á°ÀîÍÛ»Ò Å¾°ÜÀ­´Î´â¤ËÂФ¹¤ëRFA¼£ÎŤÎŬ±þ¤È¸Â³¦-ÂçIJ´â´Îž°ÜÆó¾ÉÎã¤Î¸¡Æ¤-
2004ǯ6·î Âè40²óÆüËܴδ⸦µæ²ñ ¶â¼éÎÉ ¶Ë¾®´ÎºÙ˦´â¡ÊHCC¡Ë¤ÎLpTAE¡ÜPEIT¼£ÎÅÀ®ÀӤθ¡Æ¤
2004ǯ9·î Âè81²óÆüËܾò½´ïɳزñ ÉØÌÚ½¨°ì ·«¤êÊÖ¤¹»ÉÀĻܹԤˤè¤ë´¶À÷¤Ë¤è¤êȯ¾É¤·¤¿C·¿µÞÀ­´Î±ê¤Î°ì¾ÉÎã
2004ǯ9·î ISBRA¡¡Satellite¡¡Symposium ¶â¼éÎÉ Hypervascular liver nodules in heavy drinkers of alcohol
2004ǯ10·î Âè3²ó¡¡ÆüËܴΡ³Ø²ñ¡¡Ž¼ŽÝޏŽÞŽÙŽÄŽËŽßޝޏ¡¡Ž¶ŽÝŽÌާŽÚŽÝ޽ ¶â¼éÎÉ Comparison of clinicopathological features of nonalcoholic steatohepatitis with nonalcoholic fatty liver
2004ǯ10·î DDW¡¡Japan2004 ¶â¼éÎÉ Å¾°ÜÀ­´Î´â¤ËÂФ¹¤ëRFA¼£ÎŤÎŬ±þ¤È¸Â³¦
2004ǯ10·î DDW¡¡Japan2004 »°ÅÄ·ÉÆó Ëܱ¡¤Ë¤ª¤±¤ëPEG¤Î»Ü¹Ô·Ð¸³¡¡¹çÊ»¾É¤È¤½¤ÎÂкö
2004ǯ10·î DDW¡¡Japan2004 ¶â¼éÎÉ NASH¤ÎÉÂÂ֤ˤª¤±¤ëapoptosisµÚ¤ÓºÙ˦Áý¿£³èÀ­¤Î°ÕµÁ
2005ǯ2·î Âè82²óÆüËܾò½´ïɳزñ¶áµ¦»ÙÉôÎã²ñ ¶â¼éÎÉ µÞÀ­´Î±ê¤è¤êËýÀ­²½¤ò³ÎÄꤷ¤¨¤¿genotype C, B·¿µÞÀ­´Î±ê¤Î°ì¾ÉÎã
2005ǯ2·î Âè82²óÆüËܾò½´ïɳزñ¶áµ¦»ÙÉôÎã²ñ °ÂÆ£·ò¼£ Åö±¡¤Ë¤ª¤±¤ëÁá´ü´ÎºÙ˦´â¤ËÂФ¹¤ëPEIT¤ÎĹ´ü¼£ÎÅÀ®ÀÓ
2005ǯ3·î Âè74²óÆüËܾò½´ïÆâ»ë¶À³Ø²ñ¶áµ¦ÃÏÊý²ñ ÉØÌÚ½¨°ì ¼ðáî·ÁÀ®À­ç¹±ê¤È¤Î´ÕÊ̤ËEUS-FNA¤¬Í­ÍѤǤ¢¤Ã¤¿ç¹Æ¬Éôç¹´É´â¤Î°ìÎã
2005ǯ4·î Âè91²óÆüËܾò½´ïɳزñÁí²ñ ¶â¼éÎÉ C·¿´Î¹ÅÊѤòÇØ·Ê¤ËCTAP¤Ë¤ÆÇ»À÷¡¢CTA¤Ë¤ÆË³·ìÀ­½ê¸«¤òÄ褷¤¿2¾ÉÎã
2005ǯ6·î Âè41²óÆüËܴδ⸦µæ²ñ ¶â¼éÎÉ ÈóBÈóC´Î´â¤Ë¤ª¤±¤ëÍ¢·ìÎò¤Î¸¡Æ¤¤ÈTTV¤Î´ØÍ¿
2005ǯ6·î Âè41²óÆüËܴδ⸦µæ²ñ ¶â¼éÎÉ ¥¢¥ë¥³¡¼¥ëÀ­´Î¹ÅÊѤòÇØ·Ê¤Ëȯ¾É¤·¤¿º®¹ç·¿´Î´â¤Î°ì˶¸¡¾ÉÎã
2005ǯ6·î Âè41²óÆüËܴδ⸦µæ²ñ ¶â¼éÎÉ ÆÃ°Û¤Êž°ÜÍͼ°¤òÄ褷¤¿´ÎºÙ˦´â¤ÎÆó¾ÉÎã
2005ǯ6·î Âè41²óÆüËܴδ⸦µæ²ñ ÉØÌÚ½¨°ì C·¿ËýÀ­´Î±ê¤ËÂФ¹¤ëPEG-IFN¦Á-2a¤Ë¤ª¤±¤ëpolaprezinc¤Î·ìµå¸º¾¯¤ËÂФ¹¤ë¸ú²Ì¡ÊÅêÍ¿12½µ¤Ç¤Î¸¡Æ¤¡Ë
2005ǯ6·î Âè41²óÆüËܴδ⸦µæ²ñ ¶â¼éÎÉ ´Î´â¤ËÂФ¹¤ë°Ü¿¢°åÎŤò¤á¤°¤ëÀ¸Ì¿ÎÑÍý³ØÅª¹Í»¡
2005ǯ6·î Âè176²óÆüËÜÆâ²Ê³Ø²ñÃÏÊý²ñ ÉØÌÚ½¨°ì ¿ºÌ¤Ê¹çÊ»¾É¤òʻȯ¤·¤¿¥ì¥¸¥ª¥Í¥éÇÙ±ê¤Î°ìÎã
2005ǯ9·î Âè83²óÆüËܾò½´ïɳزñ¶áµ¦»ÙÉôÎã²ñ »°ÅÄ·ÉÆó £Ã£Å£Á¾å¾º¤ò·Àµ¡¤È¤·¤Æ¼£ÎÅ¿ÇÃǤλê¤Ã¤¿²ÄưÀ­¤ÎÈó¾ï¤ËÎɹ¥¤Ç¤¢¤Ã¤¿Ãî¿â¼ðáç¤Î°ìÎã
2005ǯ9·î Âè177²óÆüËÜÆâ²Ê³Ø²ñ¶áµ¦ÃÏÊý²ñÎã²ñ ¹¿¡¡îë¼÷ ¿Í¹©¸ÆµÛ´ÉÍýÃæ¤ÎmidazolamÅêÍ¿¤Ë¤è¤êµÞÀ­´ÎÉÔÁ´¤òȯ¾É¤·¤¿µÞÀ­¥ê¥ó¥ÑÀ­Çò·ìɤξÉÎã
2005ǯ10·î DDW¡¡Japan¡¡2005 ¶â¼éÎÉ È󥢥륳¡¼¥ëÀ­»éËÃÀ­´Î±ê¡ÊNASH¡Ë¤ÎÎ×¾²ÉÂÍý³ØÅª¸¡Æ¤¡Ý»éËôΡÊFL¡Ë¤È¤ÎÈæ³Ó
2005ǯ10·î DDW¡¡Japan¡¡2005 ¶â¼éÎÉ PEG-IFN¦Á2a¤ÎÍ­¸úÀ­¡¦°ÂÁ´À­¤È°ÌÃ֤Ť±¤Ë¤Ä¤¤¤Æ
2005ǯ10·î DDW¡¡Japan¡¡2005 ÉØÌÚ½¨°ì C·¿ËýÀ­´Î±ê¤ËÂФ¹¤ëPEG-IFN¦Á2aÎÅË¡¤Ë¤ª¤±¤ë¼£ÎŸú²Ì¤ËµÚ¤Ü¤¹ISDR¤Î´ØÍ¿
2005ǯ11·î ÆüËÜÎ×¾²·ì±Õ³Ø²ñÎã²ñ ¹¿¡¡îë¼÷ ÆÃħŪÀ÷¿§ÂΞºÂ¡Êt¡Ê1:7¡Ë¡Ë¤òǧ¤áËö¾¿·ì¹¥»ÀµåÁý¿¤ª¤è¤ÓÃ×̿Ū´Ö¼ÁÀ­ÇÙ±ê¤òʻȯ¤·¤¿MDS¤Î¾ÉÎã
2005ǯ11·î Âè36²óÆüËܴΡ³Ø²ñÀ¾Éô²ñ ¶â¼éÎÉ PEG-IFN¦Á-2a¤ÎÍ­¸úÀ­¡¦°ÂÁ´À­¤È°ÌÃ֤Ť±¤Ë¤Ä¤¤¤Æ
2005ǯ11·î Âè36²óÆüËܴΡ³Ø²ñÀ¾Éô²ñ ¶â¼éÎÉ ´Î¸¶È¯À­¥«¥ë¥Á¥Î¥¤¥É¼ðáç¤Î2¾ÉÎã
2005ǯ11·î Âè36²óÆüËܴΡ³Ø²ñÀ¾Éô²ñ °æËÜÊÙ ¸¶È¯À­È󥢥륳¡¼¥ëÀ­»éËÃÀ­´Î±ê¤È­µ·¿¼«¸ÊÌȱÖÀ­´Î±ê¤Î°ì¹çÊ»Îã-ÆÃ¤Ë´Î¤ÎÉÂÍýÁÈ¿¥³ØÅª¸¡Æ¤
2005ǯ11·î Âè36²óÆüËܴΡ³Ø²ñÀ¾Éô²ñ ¶â¼éÎÉ C·¿ËýÀ­´Î±ê¤ËÂФ¹¤ëIFNÎÅË¡Ãæ¤ËÌÖËìÃæ¿´ÀÅÌ®Êĺɾɤò¹çÊ»¤·¤¿2¾ÉÎã
2005ǯ12·î Âè4²óÆüËܴΡ³Ø²ñ¥·¥ó¥°¥ë¥È¥Ô¥Ã¥¯¥«¥ó¥Õ¥¡¥ì¥ó¥¹ ¶â¼éÎÉ Long-term outcome of PEIT for small HCC less than 15mm


¢¥¤³¤Î¥Ú¡¼¥¸¤ÎTOP¤Ø

©2001-2012 KOBE ASAHI HOSPITAL. All Rights Reserved.